Scarica l'app Stockscreener
1.63
1.55%
0.02
Dopo l'orario di chiusura:
1.64
0.01
+0.61%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.61
Aprire:
$1.65
Volume 24 ore:
1.17M
Relative Volume:
0.92
Capitalizzazione di mercato:
$251.43M
Reddito:
$42.17M
Utile/perdita netta:
$-183.12M
Rapporto P/E:
-1.1194
EPS:
-1.4562
Flusso di cassa netto:
$-138.51M
1 W Prestazione:
+10.47%
1M Prestazione:
-6.57%
6M Prestazione:
+24.81%
1 anno Prestazione:
+116.24%
Intervallo 1D:
$1.63
$1.715
Intervallo di 1 settimana:
$1.47
$1.715
Portata 52W:
$0.71
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Nome
Coherus Oncology Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.63 | 248.34M | 42.17M | -183.12M | -138.51M | -1.4562 |
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Oppenheimer | Outperform |
| 2025-09-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-16 | Downgrade | UBS | Buy → Neutral |
| 2023-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2023-07-24 | Iniziato | Citigroup | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Neutral |
| 2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Iniziato | BofA Securities | Neutral |
| 2020-04-17 | Iniziato | SunTrust | Buy |
| 2019-08-13 | Iniziato | Mizuho | Buy |
| 2019-08-02 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-02 | Reiterato | Maxim Group | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-09 | Reiterato | Maxim Group | Buy |
| 2017-08-08 | Reiterato | JP Morgan | Overweight |
| 2017-06-13 | Reiterato | Maxim Group | Buy |
| 2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
| 2016-10-19 | Iniziato | Robert W. Baird | Outperform |
| 2016-09-07 | Iniziato | Maxim Group | Buy |
| 2016-07-27 | Iniziato | Citigroup | Buy |
| 2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
CHRS Should I Buy - Intellectia AI
Coherus BioSciences stock (US19247A1007): short interest remains elevated as investors watch oncolog - AD HOC NEWS
Coherus Oncology Q1 earnings call highlights - MSN
What Does The Future Hold For Coherus Oncology, Inc. (NASDAQ:CHRS)? These Analysts Have Been Cutting Their Estimates - 富途牛牛
CHRS News | COHERUS ONCOLOGY INC (NASDAQ:CHRS) - ChartMill
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook By Investing.com - Investing.com Australia
Earnings call transcript: Coherus BioSciences Q1 2026 revenue miss prompts cautious outlook - Investing.com UK
Timothy Youngquist Trust amends 13G; holds 12.75M CHRS (NASDAQ: CHRS) - Stock Titan
Coherus Oncology (CHRS) price target increased by 13.33% to 5.78 - MSN
Solid Tumor Treatment Race Heats Up as Multi-Billion-Dollar Oncology Market Enters High-Growth Phase - ChartMill
What You Need To Know About The Coherus Oncology, Inc. (NASDAQ:CHRS) Analyst Downgrade Today - Yahoo Finance
Coherus Oncology (CHRS) Q1 Loss Of US$36.9 Million Tests Bullish Growth Narratives - Sahm
Maxim Group Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Coherus Oncology, Inc. (NASDAQ:CHRS) Q1 2026 Earnings Call Transcript - Insider Monkey
Coherus Oncology: Setting Up For Important Readouts In Mid-2026 (NASDAQ:CHRS) - Seeking Alpha
Number of shareholders of Coherus Oncology, Inc. – MUN:8C5 - TradingView
Kura Oncology Q1 Earnings Call Highlights - inkl
Coherus Oncology (CHRS) Reports Q1 Earnings and Updates on LOQTO - GuruFocus
CHRS: Coherus Oncology, Inc.Interactive Chart - Zacks Investment Research
Coherus Oncology (CHRS) Reports Q1 2026 Earnings and Future Proj - GuruFocus
Coherus Oncology (CHRS) reports Q1 loss, lags revenue estimates - MSN
Coherus targets $15M quarterly LOQTORZI sales in 2026 while advancing midyear tagmokitug and casdozokitug readouts - MSN
Coherus Oncology, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology Inc (CHRS) Q1 2026 Earnings Call Highlights: St - GuruFocus
Coherus Oncology Q1 2026 Earnings Call Transcript - MarketBeat
Guggenheim initiates coverage of Coherus Oncology (CHRS) with buy recommendation - MSN
Earnings Call Summary | Coherus Oncology(CHRS.US) Q1 2026 Earnings Conference - Moomoo
Coherus Oncology Q1 Earnings Call Highlights - sharewise.com
CHRS: LOQTORZI sales surged 61% year-over-year, with robust pipeline progress and strengthened funding - TradingView
Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast By Investing.com - Investing.com South Africa
Is Coherus Oncology (CHRS) Overvalued After Q1 2026? GAAP EPS -$ - GuruFocus
CHRS Q1 2026 Earnings Transcript - The Globe and Mail
CHRS: LOQTORZI sales surged 61% year-over-year, with robust clinical and commercial momentum - TradingView
Earnings call transcript: Coherus BioSciences Q1 2026 revenue misses forecast - Investing.com Nigeria
Coherus Oncology (CHRS) Reports Q1 Loss, Lags Revenue Estimates - Yahoo Finance
Q1 2026 Coherus Oncology Inc Earnings Call Transcript - GuruFocus
Coherus Oncology (CHRS) boosts LOQTORZI sales and cash with Q1 2026 stock offering - Stock Titan
Coherus Oncology: Q1 Earnings Snapshot - 10TV
Coherus Oncology Q1 sales rise - TradingView
Coherus Oncology Reports First Quarter 2026 Financial Results and Provides Business Update - The Manila Times
CHRS: LOQTORZI revenue surged 61% year-over-year as net losses narrowed and cash reserves remained strong - TradingView
Coherus Oncology (CHRS) grows Q1 2026 revenue as losses narrow and cash hits $167M - Stock Titan
CHRS Initiated Coverage By Guggenheim -- Price Target Set at $12 - GuruFocus
Coherus Oncology Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.49%
0.12%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):